Figure 1.
Flow chart of study participation.
DIC: disseminated intravascular coagulation; DIT: drug-induced thrombocytopenia; SLE: systemic lupus erythematosus; EC: extracorporeal circulation; ECMO: extracorporeal membrane oxygenation; MARS: molecular adsorbent recirculating system.
Table 1.
The change in the platelet count and associated parameters and during continuous veno-venous hemofiltration (n = 125).
Figure 2.
Kaplan-Meier plots for cumulative 90-day survival.
Patients with a severe decline in the platelet count (≥50%) in 3-day CVVH had a worse 90-day survival than those with a mild decline in the platelet count (20–49.9%) or with no decline in the platelet count (<20%; Figure 2A). Patients with severe thrombocytopenia (Lowest Platelet count ≤50×109/L) in 3-day CVVH had a similar 90-day survival compared to those with mild thrombocytopenia (Lowest Platelet count 50.1–100×109/L) or with normal platelet counts (Lowest Platelet count>100×109/L; Figure 2B). CVVH: continuous veno-venous hemofiltration.
Table 2.
Baseline characteristics of the study population.
Table 3.
Univariate and multivariate adjusted Cox regression analyses of risk factors for mortality.
Table 4.
Univariate analyses of risk factors for a severe decline in the platelet count and severe thrombocytopenia during 3-day continuous veno-venous hemofiltration.
Table 5.
Multivariate analyses of independent risk factors for a severe decline in the platelet count and severe thrombocytopenia during 3-day continuous veno-venous hemofiltration.